Development and validation of a predictive model to guide the use of plerixafor in pediatric population

Plerixafor, a CXCR4 receptor antagonist, reduces the binding and chemotaxis of hematopoietic stem cells to the bone marrow stroma, resulting in predictable peak of cluster of differentiation 34(+) (CD34(+)) cells in the peripheral blood (PB) approximately 10 h after its administration. We developed...

Descripción completa

Detalles Bibliográficos
Autores principales: Sebastien, Bernard, Cheverton, Peter, Magnin, Catherine, Aouni, Jihane, Castan, Remi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9715428/
https://www.ncbi.nlm.nih.gov/pubmed/36163427
http://dx.doi.org/10.1038/s41409-022-01831-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9715428/
https://www.ncbi.nlm.nih.gov/pubmed/36163427
http://dx.doi.org/10.1038/s41409-022-01831-2

Ejemplares similares